Tag: Vectibix

Vectibix is the brand name for the generic drug panitumumab, a targeted monoclonal antibody therapy. While the generic name is known, Vectibix does not have a traditional generic equivalent on the market, as it is a complex biologic medication. The availability of biosimilar versions depends on patent expirations and regulatory approval.

In 2006, the U.S. Food and Drug Administration granted approval to panitumumab (brand name Vectibix) for the treatment of certain patients with metastatic colorectal cancer. The current owner of panitumumab is the global biotechnology company Amgen Inc., following a key acquisition that secured its intellectual property and commercial rights.

Originally developed by Abgenix Inc., Vectibix (panitumumab) has been manufactured and commercialized by the biopharmaceutical company Amgen Inc. since it acquired Abgenix in 2006. This acquisition gave Amgen full ownership and control over the drug, solidifying its role in bringing this important metastatic colorectal cancer treatment to market.